BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10429514)

  • 1. [The cost of innovative drugs].
    Reggio S
    Recenti Prog Med; 1999; 90(7-8):371-2. PubMed ID: 10429514
    [No Abstract]   [Full Text] [Related]  

  • 2. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 3. [Germany's Novartis Chief proposes "More competition through decentralized contracts"].
    Kosche D; Färber L
    MMW Fortschr Med; 2010 Aug; 152(31-33):6-7. PubMed ID: 20828056
    [No Abstract]   [Full Text] [Related]  

  • 4. [Follow up studies as a condition for drug subsidizing].
    Kieler H; Ekbom A; Fored M; Montgomery SM; Wettermark B
    Lakartidningen; 2009 May 13-19; 106(20):1406-7. PubMed ID: 19585842
    [No Abstract]   [Full Text] [Related]  

  • 5. [Importance of patents for the qualitative level in the evaluation of drugs].
    Rovati AL
    Boll Chim Farm; 1971 Oct; 110(10):569-72. PubMed ID: 5143354
    [No Abstract]   [Full Text] [Related]  

  • 6. [New drugs in Spain -- when are they to be considered cost-effective alternatives and profitable investments for the National Health System? ].
    Soto Alvarez J
    Farm Hosp; 2004; 28(4):299-304. PubMed ID: 15369442
    [No Abstract]   [Full Text] [Related]  

  • 7. [Ranking the efficacy of drugs--a question of "class"? It is difficult to determine equivalency of two different treatments].
    Liedholm H; Linné AB
    Lakartidningen; 2002 Sep; 99(36):3492-4, 3497-9, 3502. PubMed ID: 12362748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-patent drugs in Italy. A short-sighted view?
    Garattini L; Ghislandi S
    Eur J Health Econ; 2006 Mar; 7(1):79-83. PubMed ID: 16425040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The price of success: cost-effectiveness of molecularly targeted agents.
    Sleijfer S; Verweij J
    Clin Pharmacol Ther; 2009 Feb; 85(2):136-8. PubMed ID: 19151639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-interventional studies give good follow-up possibilities. Increased demand both nationally and internationally can be predicted].
    Strandberg K
    Lakartidningen; 2007 Sep 12-18; 104(37):2597-9. PubMed ID: 17970395
    [No Abstract]   [Full Text] [Related]  

  • 11. [Important to keep the principle of value-based pricing of drugs].
    Persson U; Levin LA; Pettersson B
    Lakartidningen; 2009 Oct 28-Nov 3; 106(44):2862-4. PubMed ID: 19967967
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug manufacturer on the savings package of Ulla Schmidt. "Grip in the moth box of planned economics"].
    Schmidt K
    MMW Fortschr Med; 2001 Nov; 143(44):52. PubMed ID: 11732398
    [No Abstract]   [Full Text] [Related]  

  • 13. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T
    Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics of adverse drug reactions.
    Lundkvist J; Jönsson B
    Fundam Clin Pharmacol; 2004 Jun; 18(3):275-80. PubMed ID: 15147278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Procedure for inscription of drugs on the Social Security reimbursement list].
    Coudurier P
    Sem Hop; 1975 Nov; 51(45):Suppl 195-8. PubMed ID: 174206
    [No Abstract]   [Full Text] [Related]  

  • 16. Italian health sector in disarray following more scandals.
    Abbott A
    Nature; 1993 Aug; 364(6439):663. PubMed ID: 8355773
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical trials and health economics--a marriage of convenience or a marriage made in heaven?
    Bakhai A; Greenberg D
    J Med Econ; 2008; 11(3):541-6. PubMed ID: 19450103
    [No Abstract]   [Full Text] [Related]  

  • 18. Should cost-effectiveness take the blame?
    McGregor M
    CMAJ; 2003 Jun; 168(12):1528; author reply 1528-9. PubMed ID: 12796326
    [No Abstract]   [Full Text] [Related]  

  • 19. Spiraling drug costs: a call for cost-effective prescribing.
    Good CB
    J Am Geriatr Soc; 2005 Aug; 53(8):1427-9. PubMed ID: 16078975
    [No Abstract]   [Full Text] [Related]  

  • 20. [From the very valuable therapy, to the high cost of a new drug: a growing hiatus].
    Scheen AJ
    Rev Med Suisse; 2005 Aug; 1(30):1931-2. PubMed ID: 16200935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.